HARMONY BIOSCIENCES HOLDINGS, INC. Dilutive Share Adjustment
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Dilutive Share Adjustment of 902.75 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment · last filed 2024-02-22
- HARMONY BIOSCIENCES HOLDINGS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2023 was 902.75K shares, a 53.08% decline from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2022 was 1.92M shares, a 14.95% increase from fiscal 2021.
- HARMONY BIOSCIENCES HOLDINGS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2021 was 1.67M shares.
| Period end | Weighted Average Number Diluted Shares Outstanding Adjustment 12 month |
|---|---|
| 2023-12-31 | 902.75K shares 10-K · filed 2024-02-22 |
| 2022-12-31 | 1.92M shares 10-K · filed 2024-02-22 |
| 2021-12-31 | 1.67M shares 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |